Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Nivolumab and Relatlimab for Advanced Melanoma - NCI

Updated Data for First-Line Immunotherapy Combinations Reinforce Their Value in Metastatic Melanoma

Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis - ScienceDirect

Melanoma brain metastases, immunotherapy as standard of care

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. - Abstract - Europe PMC

Ipilimumab Plus Nivolumab Improves Survival in Melanoma With Brain Metastases - Cancer Therapy Advisor

Updated Data From Clinical Trials on Nivolumab/Ipilimumab in Advanced Melanoma - The ASCO Post

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study - ScienceDirect

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study - The Lancet Oncology

The Efficacy and Safety of Immune Checkpoint Inhibitors in Treating Melanoma

ABC-X Clinical Trial - Melanoma Institute Australia

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

MBM - Melanoma Brain Metastases

MBM - Melanoma Brain Metastases